Literature DB >> 2908719

Secondary prevention after myocardial infarction: effects of beta blocking agents and calcium antagonists.

P Depelchin1, J Sobolski, M Jottrand, C Flament.   

Abstract

Therapeutic interventions in patients with myocardial infarction, whether during the first hours after coronary occlusion or several days later, aim to reduce mortality and morbidity by several mechanisms: Prevention of fatal ventricular fibrillation, limitation of infarct size, and inhibition of platelet aggregation are some examples of such mechanisms. Results from early intervention trials with beta blocking agents, particularly from ISIS-I, suggest that 1-year mortality is significantly lower in selected patients randomized to active treatment. Late intervention studies also suggest a significant reduction in coronary mortality and morbidity with beta blockade, particularly when data are pooled. Studies with the calcium channel blockers nifedipine and verapamil were unable to demonstrate any beneficial effects of these drugs on mortality or reinfarction. In this review article, attention will be directed to the most recent information about the preventive value of beta adrenergic blocking drugs and slow calcium channel inhibitors.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2908719     DOI: 10.1007/BF00054265

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  40 in total

1.  Propranolol in the treatment of acute myocardial infarction. Effect on myocardial oxygenation and hemodynamics.

Authors:  H S Mueller; S M Ayres; A Religa; R G Evans
Journal:  Circulation       Date:  1974-06       Impact factor: 29.690

Review 2.  Coronary thrombolysis.

Authors:  D de Bono
Journal:  Br Heart J       Date:  1987-04

3.  European Infarction Study (E.I.S.). A secondary prevention study with slow release oxprenolol after myocardial infarction: morbidity and mortality.

Authors: 
Journal:  Eur Heart J       Date:  1984-03       Impact factor: 29.983

4.  Controlled trial of sotalol for one year after myocardial infarction.

Authors:  D G Julian; R J Prescott; F S Jackson; P Szekely
Journal:  Lancet       Date:  1982-05-22       Impact factor: 79.321

5.  Early thrombolysis in acute myocardial infarction: limitation of infarct size and improved survival.

Authors:  M L Simoons; P W Serruys; M van den Brand; J Res; F W Verheugt; X H Krauss; W J Remme; F Bär; C de Zwaan; A van der Laarse
Journal:  J Am Coll Cardiol       Date:  1986-04       Impact factor: 24.094

Review 6.  The role of beta-blockers in the treatment of patients after infarction.

Authors:  C M Pratt; J B Young; R Roberts
Journal:  Cardiol Clin       Date:  1984-02       Impact factor: 2.213

7.  Nifedipine limits infarct size for 24 hours in closed chest coronary embolized dogs.

Authors:  S Yoshida; J M Downey; F R Friedman; D E Chambers; D J Hearse; D M Yellon
Journal:  Basic Res Cardiol       Date:  1985 Jan-Feb       Impact factor: 17.165

8.  Reduction of ventricular arrhythmias by early intravenous atenolol in suspected acute myocardial infarction.

Authors:  P R Rossi; S Yusuf; D Ramsdale; L Furze; P Sleight
Journal:  Br Med J (Clin Res Ed)       Date:  1983-02-12

9.  Stopping smoking and long-term mortality after acute myocardial infarction.

Authors:  J T Salonen
Journal:  Br Heart J       Date:  1980-04

10.  Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. First International Study of Infarct Survival Collaborative Group.

Authors: 
Journal:  Lancet       Date:  1986-07-12       Impact factor: 79.321

View more
  1 in total

Review 1.  Predicting acute kidney injury: current status and future challenges.

Authors:  Simona Pozzoli; Marco Simonini; Paolo Manunta
Journal:  J Nephrol       Date:  2017-06-17       Impact factor: 3.902

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.